Belgium Approves Extension Trial of Abivax’s Ulcerative Colitis Therapy

Belgium Approves Extension Trial of Abivax’s Ulcerative Colitis Therapy
Regulators in Belgium have approved Abivax’s request for a long-term extension of the company’s ongoing Phase 2a trial of ABX464 as a treatment for ulcerative colitis. It said it expects approvals from regulators in a number of other European countries as well. Abiva originally developed ABX464 to treat HIV/AIDS. But it discovered that the compound had anti-inflammatory properties that

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *